Drugs / DTaP5-HBV-IPV-Hib
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04535037 Comparator | May 2021 → Jul 2022 | diphtheria | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP5-HBV-IPV-Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04535037 ↗ |
| Modality | Vaccine | “DTaP5-HBV-IPV-Hib vaccine” NCT04535037 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT04535037 ↗ |